Filter

Refine by collections

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 91 - 100 of 2,510 items for :

  • Refine by access: All content x
Clear All
Jennifer A Woyach Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA

Search for other papers by Jennifer A Woyach in
Google Scholar
PubMed Close
and
Manisha H Shah Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA

Search for other papers by Manisha H Shah in
Google Scholar
PubMed Close

Background Thyroid cancer is the most common malignancy of the endocrine system, and a disease whose incidence has been increasing over the past 20 years ( Davies & Welch 2006 ). This heterogeneous disease is classified into differentiated thyroid

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-08-0335
Volume/Issue:
Volume 16: Issue 3
Free access
Emma-Leena Alarmo Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 Tampere, Finland

Search for other papers by Emma-Leena Alarmo in
Google Scholar
PubMed Close
and
Anne Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 Tampere, Finland

Search for other papers by Anne Kallioniemi in
Google Scholar
PubMed Close

. 1988 , Reddi 1997 , Wozney 2002 ); currently, they are well known to play critical roles in diverse developmental phases ( Hogan 1996 a , Zhao 2003 ). These kinds of powerful developmental pathways are frequently disrupted in cancer ( Kelleher et al

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-09-0273
Volume/Issue:
Volume 17: Issue 2
Free access
A M Lorincz
Search for other papers by A M Lorincz in
Google Scholar
PubMed Close
and
S Sukumar
Search for other papers by S Sukumar in
Google Scholar
PubMed Close

Obesity and breast cancer Over 40 000 women in the USA die each year of metastatic breast cancer, for which there are currently no permanent cures. In fact, about one-half of women with metastatic disease who undergo therapeutic

Article Type:
Review Article
DOI:
https://doi.org/10.1677/erc.1.00729
Volume/Issue:
Volume 13: Issue 2
Free access
R A Stein Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA

Search for other papers by R A Stein in
Google Scholar
PubMed Close
and
D P McDonnell Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA

Search for other papers by D P McDonnell in
Google Scholar
PubMed Close

Introduction Drugs that function by inhibiting ERα signaling have been and will continue to be an important part of pharmacotherapy in breast cancer. Foremost among these therapies are selective estrogen receptor modulators (SERMs

Article Type:
Research Article
DOI:
https://doi.org/10.1677/erc.1.01292
Volume/Issue:
Volume 13: Issue Supplement_1
Free access
Lei Gu Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Lei Gu in
Google Scholar
PubMed Close
,
Paraskevi Vogiatzi Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Paraskevi Vogiatzi in
Google Scholar
PubMed Close
,
Martin Puhr Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Martin Puhr in
Google Scholar
PubMed Close
,
Ayush Dagvadorj Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Ayush Dagvadorj in
Google Scholar
PubMed Close
,
Jacqueline Lutz Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Jacqueline Lutz in
Google Scholar
PubMed Close
,
Amy Ryder Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Amy Ryder in
Google Scholar
PubMed Close
,
Sankar Addya Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Sankar Addya in
Google Scholar
PubMed Close
,
Paolo Fortina Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Paolo Fortina in
Google Scholar
PubMed Close
,
Carlton Cooper Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Carlton Cooper in
Google Scholar
PubMed Close
,
Benjamin Leiby Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Benjamin Leiby in
Google Scholar
PubMed Close
,
Abhijit Dasgupta Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Abhijit Dasgupta in
Google Scholar
PubMed Close
,
Terry Hyslop Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Terry Hyslop in
Google Scholar
PubMed Close
,
Lukas Bubendorf Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Lukas Bubendorf in
Google Scholar
PubMed Close
,
Kalle Alanen Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Kalle Alanen in
Google Scholar
PubMed Close
,
Tuomas Mirtti Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Tuomas Mirtti in
Google Scholar
PubMed Close
, and
Marja T Nevalainen Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Cancer Biology, Medicina Sperimentale e Patologia, Biological Sciences, Pharmacy and Experimental Therapeutics, Institute for Pathology, Pathology, Urology, Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Search for other papers by Marja T Nevalainen in
Google Scholar
PubMed Close

Introduction The complex molecular mechanisms underlying the progression of prostate cancer from organ-confined tumor to metastatic disease are largely unknown. Identification of the molecular changes associated with the metastasis process of

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-09-0328
Volume/Issue:
Volume 17: Issue 2
Free access
Sarah A Dabydeen Departments of Oncology, Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Research Building, Room 520A, Washington, District of Columbia 20057, USA

Search for other papers by Sarah A Dabydeen in
Google Scholar
PubMed Close
and
Priscilla A Furth Departments of Oncology, Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Research Building, Room 520A, Washington, District of Columbia 20057, USA
Departments of Oncology, Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Research Building, Room 520A, Washington, District of Columbia 20057, USA

Search for other papers by Priscilla A Furth in
Google Scholar
PubMed Close

Introduction Breast cancer is a heterogeneous disease consisting of four clinically relevant categories based on the expression patterns of estrogen receptor α (ERα; ESR1 ) and V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 2 ( HER2

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-13-0512
Volume/Issue:
Volume 21: Issue 3
Free access
T M Murphy Prostate Cancer Research Group, Institute of Molecular Medicine, Trinity College Dublin, Ireland

Search for other papers by T M Murphy in
Google Scholar
PubMed Close
,
A S Perry Prostate Cancer Research Group, Institute of Molecular Medicine, Trinity College Dublin, Ireland

Search for other papers by A S Perry in
Google Scholar
PubMed Close
, and
M Lawler Prostate Cancer Research Group, Institute of Molecular Medicine, Trinity College Dublin, Ireland

Search for other papers by M Lawler in
Google Scholar
PubMed Close

Introduction Prostate cancer represents a global public health problem. Worldwide, it is the second most common noncutaneous cancer in men, accounting for ∼10% of male cancers ( Parkin et al . 2005 ). Prostate cancer is the second leading cause of

Article Type:
Research Article
DOI:
https://doi.org/10.1677/ERC-07-0208
Volume/Issue:
Volume 15: Issue 1
Free access
Craig J Burd
Search for other papers by Craig J Burd in
Google Scholar
PubMed Close
,
Lisa M Morey
Search for other papers by Lisa M Morey in
Google Scholar
PubMed Close
, and
Karen E Knudsen
Search for other papers by Karen E Knudsen in
Google Scholar
PubMed Close

notably prostate cancer. Prostatic adenocarcinoma is the most commonly diagnosed malignancy and the second leading cause of male cancer death in most western countries, including the United States ( Denmeade & Isaacs 2002 , Jemal et al. 2006

Article Type:
Review Article
DOI:
https://doi.org/10.1677/erc.1.01115
Volume/Issue:
Volume 13: Issue 4
Free access
Emma H Allott Department of Epidemiology, Lineberger Comprehensive Cancer Center, Department of Nutrition, CB 7435, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA
Department of Epidemiology, Lineberger Comprehensive Cancer Center, Department of Nutrition, CB 7435, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA

Search for other papers by Emma H Allott in
Google Scholar
PubMed Close
and
Stephen D Hursting Department of Epidemiology, Lineberger Comprehensive Cancer Center, Department of Nutrition, CB 7435, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA
Department of Epidemiology, Lineberger Comprehensive Cancer Center, Department of Nutrition, CB 7435, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA

Search for other papers by Stephen D Hursting in
Google Scholar
PubMed Close

Introduction Cancer is predicted to overtake heart disease as the leading cause of death across all age groups in the U.S. by 2030, translating to a 45% increase in the number of cancer diagnoses in the next 15 years ( American Society of Clinical

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-15-0400
Volume/Issue:
Volume 22: Issue 6
Free access
Liyan Zhou Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Liyan Zhou in
Google Scholar
PubMed Close
,
Guiying Bai Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Guiying Bai in
Google Scholar
PubMed Close
,
Yue Song Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yue Song in
Google Scholar
PubMed Close
,
Xiaohui Liu Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Xiaohui Liu in
Google Scholar
PubMed Close
,
Xiaoqing Li Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Xiaoqing Li in
Google Scholar
PubMed Close
,
Yilin Deng Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yilin Deng in
Google Scholar
PubMed Close
,
Yiran Si Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yiran Si in
Google Scholar
PubMed Close
,
Yehui Shi Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yehui Shi in
Google Scholar
PubMed Close
, and
Hongli Li Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Hongli Li in
Google Scholar
PubMed Close

Introduction Breast cancer is the most prevalent malignant tumor in women worldwide, significantly affecting the quality of life and threatening the health of women ( Giaquinto et al. 2022 ). Multiple meta-analyses have shown that the risk

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-23-0330
Volume/Issue:
Volume 31: Issue 9
Restricted access